Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 48, Issue 4, 2003, Pages 670-676

  Chiu, Cheng Tang ^a   Yeh, Ta Sen ^a,b   Hsu, Jui Chen ^a   Chen, Mün Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bax; Bcl 2; Bcl xL; Bcl xS; Hepatocellular carcinoma; p21; p53

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BCL XS; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE HOMOGENATE; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; HUMANS; IN SITU NICK-END LABELING; LIVER; LIVER NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0037380281     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022816204831     Document Type: Article

References (18)

1. Frommel TO, Yong S, Zarling EJ: Immunohistochemical evaluation of bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Am J Gastroenterol 94:178-182, 1999
2. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3:614-620, 1997
3. S in p53 overexpressing hepatocellular carcinona. Biochem Biophys Res Commun 273:54-61, 2000
4. Takehara T, Liu X, Fujimoton J, et al: Expression and role of Bcl-xL in human hepatocellular carcinoma. Hepatology 34:55-61, 2001
5. Krajewiski S, Krajewska M, Shabaik A, et al: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323-1336, 1994
6. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
7. Selvakumaran M, Lin HK, Miyashita T, et al: Immediate early upregulation of bax expression by p53 but not TGF-β: a paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798, 1994
8. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
9. Hsu IC, metcalf RA, Sun T, et al: Mutational hot spot in the p53 gene in human hepatocellular carcinoma. Nature 350:427-428, 1991
10. Bressac B, Kew M, Wands J, et al: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 35:429-431, 1991
11. Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated GI arrest in human cancer cells. Cancer Res 55:5187-5190, 1995
12. Yang ZY, Perkins ND, Ohno T, et al: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vitro. Nature Med 1:1052-1056, 1995
13. Shi YZ, Takayama T, Li X, et al: Reduced p21 WAF1/CIP1 protein expression is predominatly related to altered p53 in hepatocellular carcinoma. Br J Cancer 83:50-55, 2000
14. El-Deity WS: p53, p21 and the control of cell proliferation. In Apoptosis and Cell Cycle Control in Cancer. NSB Thomas (ed). Oxford, BIOS Scientific Publishers, 1996, pp 65-75
15. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature 362:849-852, 1993
16. Lowe SW, Earl Ruley H, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
17. Oltvaj ZN, Milliman CL, Krosmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74:609-619, 1993
18. Mitry RR, Sarraf CE, Wu CG, et al: Wild-type p53 induces apoptosis in Hep3B through up-regulation of Bax expression. Lab Invest 77:369-378, 1997